Axsome Therapeutics reported a quarterly loss of $1.26 per share, missing the Zacks Consensus Estimate for a $0.85 loss by $0.41. The loss also widened versus $0.80 per share a year ago, indicating deteriorating profitability on a year-over-year basis. The headline is negative for sentiment, though the article contains no revenue or guidance details.
Axsome Therapeutics reported a quarterly loss of $1.26 per share, missing the Zacks Consensus Estimate for a $0.85 loss by $0.41. The loss also widened versus $0.80 per share a year ago, indicating deteriorating profitability on a year-over-year basis. The headline is negative for sentiment, though the article contains no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
